Drug Profile
Combination seasonal influenza RSV nanoparticle vaccine - Novavax
Alternative Names: Combination seasonal influenza-RSV vaccine - Novavax; Combination Seasonal Influenza/RSV F Vaccine - Novavax; Combo RSV/Flu vaccine - Novavax; NanoFlu/RSV - Novavax; NanoFlu/RSV combination vaccine - Novavax; RSV-influenza combination vaccine - Novavax; RSV-influenza nanoparticle vaccine - Novavax; RSV-influenza vaccine - Novavax; RSV/Flu vaccine - NovavaxLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Novavax
- Class Influenza virus vaccines; Protein vaccines; Respiratory syncytial virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections; Respiratory syncytial virus infections
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (Parenteral)
- 28 May 2023 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections(Prevention) in USA (Parenteral)
- 01 Mar 2021 Preclinical development is ongoing in Influenza virus infections (Prevention) in USA (Parenteral)